Steven N. Singh
Research Subjects
Steven N. Singh has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Bramah N. Singh
Department of Cardiology, Veterans Affairs Medical Center, Los Angeles, California
3 shared publicationsAlan K. Jacobson
2 shared publicationsBecky Lopez
2 shared publicationsDomenic J. Reda
2 shared publicationsJonathan Patrick
2 shared publicationsMichael D. Ezekowitz
2 shared publications
Latest Publications
- Open Access
- 1 March 2012
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. 4, 79-90
Costs and clinical consequences of suboptimal atrial fibrillation management
Peer reviewed article authored by (Singh SN). Read article or submit your manuscript for publishing.
- 1 March 2012
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. 4, 79-90
Open AccessCosts and clinical consequences of suboptimal atrial fibrillation management
Peer reviewed article authored by (Singh SN). Read article or submit your manuscript for publishing.
- 1 August 2011
- Published by Oxford University Press (OUP)
- p. 340-344
Ventricular arrhythmias in heart failure: link to haemodynamic load
- 1 August 2011
- Published by Oxford University Press (OUP)
- p. 340-344
Ventricular arrhythmias in heart failure: link to haemodynamic load
- 1 June 2009
- Vol. 15, S185-92
The burden and management of TIA and stroke in the Veterans Administration and Department of Defense.
Transient ischemic attack (TIA) and stroke are commonly occurring cerebrovascular events that require prompt and appropriate treatment to reduce the risk of secondary stroke. The US Department of Veterans Affairs (VA) and the Department of Defense constitute 2 large medical systems treating military personnel, both active and retired, as well as many of their dependents. In the area of stroke and TIA management, the VA in particular has instituted far-reaching measures, including those to ensure adherence to clinical treatment guidelines shown to produce optimal outcomes in stroke. The result of these measures has been that VA patients experience lower morbidity and mortality risk, as well as lower rates of stroke-related rehospitalization, than comparable patients treated through Medicare and Medicaid and in university hospitals. These successes in part may be an advantage derived from a relatively closed system with sufficient administrative discipline to maintain clinical guidelines treatment standards. It may also be the case that continuity of care in these systems produces better outcomes than more fragmentary treatment that may be experienced in the civilian realm. In addition, the VA system avoids incentivizing physicians for performing medical services, and instead incentivizes quality of care, which may provide a further advantage for patients treated within that system.
- 1 June 2009
- Vol. 15, S185-92
The burden and management of TIA and stroke in the Veterans Administration and Department of Defense.
Transient ischemic attack (TIA) and stroke are commonly occurring cerebrovascular events that require prompt and appropriate treatment to reduce the risk of secondary stroke. The US Department of Veterans Affairs (VA) and the Department of Defense constitute 2 large medical systems treating military personnel, both active and retired, as well as many of their dependents. In the area of stroke and TIA management, the VA in particular has instituted far-reaching measures, including those to ensure adherence to clinical treatment guidelines shown to produce optimal outcomes in stroke. The result of these measures has been that VA patients experience lower morbidity and mortality risk, as well as lower rates of stroke-related rehospitalization, than comparable patients treated through Medicare and Medicaid and in university hospitals. These successes in part may be an advantage derived from a relatively closed system with sufficient administrative discipline to maintain clinical guidelines treatment standards. It may also be the case that continuity of care in these systems produces better outcomes than more fragmentary treatment that may be experienced in the civilian realm. In addition, the VA system avoids incentivizing physicians for performing medical services, and instead incentivizes quality of care, which may provide a further advantage for patients treated within that system.
- 28 February 2009
- Published by Elsevier in Heart Rhythm
- Vol. 6 (2) , 152-155
Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: A substudy of the SAFE-T trial
- 28 February 2009
- Published by Elsevier in Heart Rhythm
- Vol. 6 (2) , 152-155
Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: A substudy of the SAFE-T trial
- 1 September 2007
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 12 (3) , 175-180
Implantable Cardioverter Defibrillator Therapy and the Need for Concomitant Antiarrhythmic Drugs
Prior studies have suggested that intravenous diltiazem reduces the probability of spontaneous conversion of atrial fibrillation (AF) to sinus rhythm in the electrophysiology laboratory and in patients with postoperative AF. Whether diltiazem exerts the same effect in patients presenting to the emergency department (ED) with spontaneous AF is unclear. Fifty patients presenting to the ED with new-onset or paroxysmal AF and a rapid ventricular rate (>100 beats per minute) were randomly assigned to receive intravenous diltiazem or esmolol during the first 24 hours of presentation. Conversion to sinus rhythm occurred in 10 patients (42%) in the diltiazem group compared with 10 patients (39%) in the esmolol group (P = 1.0). Diltiazem does not decrease the likelihood of spontaneous conversion of AF to sinus rhythm in the ED setting.
- 1 September 2007
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 12 (3) , 175-180
Implantable Cardioverter Defibrillator Therapy and the Need for Concomitant Antiarrhythmic Drugs
Prior studies have suggested that intravenous diltiazem reduces the probability of spontaneous conversion of atrial fibrillation (AF) to sinus rhythm in the electrophysiology laboratory and in patients with postoperative AF. Whether diltiazem exerts the same effect in patients presenting to the emergency department (ED) with spontaneous AF is unclear. Fifty patients presenting to the ED with new-onset or paroxysmal AF and a rapid ventricular rate (>100 beats per minute) were randomly assigned to receive intravenous diltiazem or esmolol during the first 24 hours of presentation. Conversion to sinus rhythm occurred in 10 patients (42%) in the diltiazem group compared with 10 patients (39%) in the esmolol group (P = 1.0). Diltiazem does not decrease the likelihood of spontaneous conversion of AF to sinus rhythm in the ED setting.
- 1 October 2004
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 6 (5) , 357-364
Antiarrhythmic drugs
- 1 October 2004
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 6 (5) , 357-364
Antiarrhythmic drugs
- 1 February 2004
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 10 (S1) , 71-76
Trials of New Antiarrhythmic Drugs for Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation
Despite the recent results of the AFFIRM trail showing that either strategy of rate control or rhythm control is acceptable, there is general agreement that therapy must be individualized. Antiarrhythmic drugs while being effective in maintaining sinus rhythm are not without side effects. Thus, there continues to be a search for safer and better tolerated agents. Azimilide is a novel class 3 agent that blocks both components of the delayed rectifier current, while dofetilide blocks only the slow component. Dronedarone is somewhat similar to aminodarone, but perhaps with the side effects. Tedisamil is a complex class 3 agent, blocking multiple channels. Piboserod is a selective 5-HT receptor antagonist that is being investigated in clinical trials.
- 1 February 2004
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 10 (S1) , 71-76
Trials of New Antiarrhythmic Drugs for Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation
Despite the recent results of the AFFIRM trail showing that either strategy of rate control or rhythm control is acceptable, there is general agreement that therapy must be individualized. Antiarrhythmic drugs while being effective in maintaining sinus rhythm are not without side effects. Thus, there continues to be a search for safer and better tolerated agents. Azimilide is a novel class 3 agent that blocks both components of the delayed rectifier current, while dofetilide blocks only the slow component. Dronedarone is somewhat similar to aminodarone, but perhaps with the side effects. Tedisamil is a complex class 3 agent, blocking multiple channels. Piboserod is a selective 5-HT receptor antagonist that is being investigated in clinical trials.
- 1 September 2003
- Published by Springer Nature in Cardiac Electrophysiology Review
- Vol. 7 (3) , 225-228
Role of Dofetilide in Patients with Atrial Fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study
Dofetilide is a class III antiarrhythmic drug (potassium channel blocker) that has been approved by the regulatory agencies in the United States and throughout the world to convert atrial fibrillation and maintain sinus rhythm. Therapy is initiated in-hospital during heart rhythm monitoring. Doses are selected according to the QT interval and estimated creatinine clearance. In patients with heart failure and prior myocardial infarction, dofetilide was very effective in converting atrial fibrillation and maintaining normal sinus rhythm. In patients with persistent atrial fibrillation, dofetilide compared to placebo was significantly better in converting atrial fibrillation and maintaining sinus rhythm. This was especially true for the highest dose of 500 μg twice-a-day. Caution must be used when initiating dofetilide therapy to avoid torsade de pointes ventricular tachycardia, especially in patients with heart failure, hypertrophy, bradycardia and female gender.
- 1 September 2003
- Published by Springer Nature in Cardiac Electrophysiology Review
- Vol. 7 (3) , 225-228
Role of Dofetilide in Patients with Atrial Fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study
Dofetilide is a class III antiarrhythmic drug (potassium channel blocker) that has been approved by the regulatory agencies in the United States and throughout the world to convert atrial fibrillation and maintain sinus rhythm. Therapy is initiated in-hospital during heart rhythm monitoring. Doses are selected according to the QT interval and estimated creatinine clearance. In patients with heart failure and prior myocardial infarction, dofetilide was very effective in converting atrial fibrillation and maintaining normal sinus rhythm. In patients with persistent atrial fibrillation, dofetilide compared to placebo was significantly better in converting atrial fibrillation and maintaining sinus rhythm. This was especially true for the highest dose of 500 μg twice-a-day. Caution must be used when initiating dofetilide therapy to avoid torsade de pointes ventricular tachycardia, especially in patients with heart failure, hypertrophy, bradycardia and female gender.